(Q50066887)

24 February 2018

title

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. (English)

1 reference

24 February 2018

1 reference

1 reference

Stephen V Liu

12

0 references

Giuseppe Giaccone

1

Giuseppe Giaccone

1 reference

24 February 2018

Subramaniam Nachimuthu Deepa

11

Deepa S Subramaniam

1 reference

24 February 2018

Jillian Thompson

3

Jillian Thompson

1 reference

24 February 2018

Justine N McCutcheon

14

Justine N McCutcheon

1 reference

24 February 2018

author name string

Chul Kim

2

1 reference

24 February 2018

Colleen McGuire

4

1 reference

24 February 2018

Bhaskar Kallakury

5

1 reference

24 February 2018

Joeffrey J Chahine

6

1 reference

24 February 2018

Maria Manning

7

1 reference

24 February 2018

Robin Mogg

8

1 reference

24 February 2018

Wendy M Blumenschein

9

1 reference

24 February 2018

Ming T Tan

10

1 reference

24 February 2018

Ian M Kaplan

13

1 reference

24 February 2018

publication date

25 January 2018

1 reference

24 February 2018

Lancet Oncology Commission

published in

1 reference

24 February 2018

Epidemiology of thymoma and associated malignancies

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Thymic malignancies: from clinical management to targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Diffuse high intensity PD-L1 staining in thymic epithelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Follow-up study of thymomas with special reference to their clinical stages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Autoimmune regulator expression in thymomas with or without autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

The Integrated Genomic Landscape of Thymic Epithelial Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Multiorgan autoimmune manifestations associated with thymoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Mutations of epigenetic regulatory genes are common in thymic carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

Inherited cylindromas: lessons from a rare tumour

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930062-7

7 January 2021

10.1016/S1470-2045(18)30062-7

Identifiers

DOI

1 reference

24 February 2018

1 reference

24 February 2018